Article

Routine prophylactic application of Monsel's solution after loop electrosurgical excision procedure of the cervix: is it necessary?

Department of Obstetrics and Gynecology, Gynecologic Oncology Division, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Journal of Obstetrics and Gynaecology Research (Impact Factor: 0.84). 07/2007; 33(3):299-304. DOI: 10.1111/j.1447-0756.2007.00528.x
Source: PubMed

ABSTRACT To determine the benefit of an immediate application of Monsel's solution after loop electrosurgical excision procedure (LEEP) of the cervix for preventing postoperative bleeding.
This randomized controlled trial was conducted at Chiang Mai University Hospital, Chang Mai, Thailand. Women who were scheduled for LEEP were approached for participation in the study. The primary endpoint was the duration of uncomplicated vaginal bleeding. Secondary endpoints were the incidence of persistent vaginal bleeding, and postoperative complications including severe early bleeding, severe delayed bleeding and infection.
Between October 2004 and May 2006, 285 women with an abnormal Pap-smear, who had undergone LEEP, were randomly allocated to the Monsel's group (n = 140) or control group (n = 145). The baseline outcomes were similar between the two groups. In the Monsel's group, the duration of uncomplicated vaginal bleeding was significantly shorter (P < 0.001) and the occurrence of persistent vaginal bleeding was significantly lower (P = 0.014) than in the control group. The occurrence of severe complications that required treatment, including bleeding and infection, was not significantly different between the two groups (P = 0.379).
An application of Monsel's solution after LEEP appears to reduce the duration of postoperative vaginal bleeding, but does not significantly prevent severe complications. Such practice may not be necessary if adequate hemostasis is achieved using electrical cauterization.

1 Bookmark
 · 
115 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To compare the complications and success rate of Contour-Loop Excision of the Transformation Zone (C-LETZ) with Cold Knife Conization (CKC) in High Grade Lesion (HGL). Between April 1st, 2007 and November 30th, 2007, forty-five C-LETZs were performed in patients who had Pap smear result of High grade Squamous Intraepithelial Lesion (HSIL) or Squamous Cell Carcinoma (SCC) combined with colposcopic impression of satisfactory HGL by using the "See and Treat" approach. Success rate, tissue size, operating time, blood loss, intra-operative, and post-operative complications (2 weeks) were recorded to compare with the retrospective results from therapeutic CKC. Forty-five cases of C-LETZ and 50 cases of CKC were compared. Using the "See and Treat" approach, the over-treatment rate was 6.7% (3/45). The success rate and tissue size were not different between both groups. The operating time, blood loss, and post-operative infection were significantly less in the C-LETZ group. The authors compared CKC with C-LETZ, which is a new method for the management ofHGL of the cervix and found C-LETZ to be a favorable method with comparable efficacy but with significantly less morbidity, and suitable as a "See and Treat" method in a hospital outpatient clinic.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet 12/2009; 92(12):1573-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cervical intraepithelial neoplasia (CIN) II, III is a preinvasive stage of squamous cell carcinoma of the uterine cervix. The standard treatment for CIN II, III consists of ablation and excision. However, nonsurgical treatment may be necessary for some women to preserve future reproductive potential. This review was conducted to summarize available published data on the efficacy and safety of medical treatment for CIN II, III. Based on existing studies, cyclooxygenase (COX)-2 inhibitors; indole-3-carbinol; and novel immunotherapy agents, including ZYC101a, MVA E2, and HspE7, have been observed as possessing therapeutic activity without any major treatment-related complications. These promising results provide important data for the future direction of clinical research.
    International Journal of Clinical Oncology 03/2009; 14(1):37-42. · 1.73 Impact Factor